Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Adrià Bernat‐Peguera
Observed names:
A. Bernat,
A. Bernat Peguera,
A. Bernat-Peguera,
Adrià Bernat,
Adrià Bernat Peguera,
Adrià Bernat-Peguera
show all 6
Institution:
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
Observed institutions:
Universitat Autònoma de Barcelona,
Institut d'Investigació Biomédica de Bellvitge,
Josep Carreras Leukaemia Research Institute,
Institut Català d'Oncologia,
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol,
Hospital Universitari Germans Trias i Pujol
show all 6
ORCID:
0000-0002-3108-0571
Observed ORCID:
0000-0002-3108-0571
OpenAlex ID:
A5004112048
Cancer cell plasticity: Impact on tumor progression and therapy response
2018
·
Victoria da Silva-Diz
, Laura Lorenzo-Sanz
, et al.
·
Seminars in Cancer Biology
·
233
Role of ctDNA in Breast Cancer
2022
·
Marta Sant
, Adrià Bernat-Peguera
, et al.
·
Cancers
·
111
PDF
The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity
2025
·
Mustafa Sibai
, Sergi Cervilla
, et al.
·
Cell Reports
·
55
PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma
2019
·
Adrià Bernat-Peguera
, Pilar Simón-Extremera
, et al.
·
Oncogene
·
44
PDF
Cancer Stem-like Cells Act via Distinct Signaling Pathways in Promoting Late Stages of Malignant Progression
2016
·
Victoria da Silva-Diz
, Pilar Simón-Extremera
, et al.
·
Cancer Research
·
33
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
2020
·
Adrià Bernat-Peguera
, Juan Navarro-Ventura
, et al.
·
Clinical Cancer Research
·
23
PDF
Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small-cell lung cancer and no other actionable oncogenic driver
2021
·
Marta Domènech
, Ana M. Muñoz Marmol
, et al.
·
Oncotarget
·
20
PDF
Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer
2024
·
Vicenç Ruiz de Porras
, Adrià Bernat-Peguera
, et al.
·
Frontiers in Pharmacology
·
15
PDF
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
2022
·
Adrià Bernat-Peguera
, Macedonia Trigueros
, et al.
·
The Breast
·
11
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy
2024
·
Iris Teruel
, Eva Castellà
, et al.
·
International Journal of Molecular Sciences
·
8
PDF
SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
2023
·
Lucía Gutiérrez-Chamorro
, Eudald Felip
, et al.
·
Frontiers in Immunology
·
5
PDF
Deciphering HER2-low breast cancer (BC): insights from real-world data in early stage breast cancer
2024
·
Anna Pous
, Adrià Bernat-Peguera
, et al.
·
Therapeutic Advances in Medical Oncology
·
4
1658P Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)
2021
·
A. Plaja
, T. Moran
, et al.
·
Annals of Oncology
·
3
Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
2025
·
Eudald Felip
, Edurne Garcia‐Vidal
, et al.
·
Clinical and Translational Medicine
·
2
PDF
Abstract A003: Mapping the tumor microenvironment: Spatial Transcriptomic insights into ovarian cancer progression and resistance
2025
·
Kathleen Imbach
, Sergi García
, et al.
·
Cancer Research
·
1
Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel‐plus‐cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
2024
·
Beatriz Cirauqui Cirauqui
, Adrià Bernat Peguera
, et al.
·
Head & Neck
·
1
PDF
Exploring HER2-low disease: Does it impact breast cancer survival?
2023
·
Assumpció López-Paradís
, Anna Pous
, et al.
·
Journal of Clinical Oncology
·
1
PDF
583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model
2022
·
J.A. Perez Fidalgo
, J.J. Martinez Pretel
, et al.
·
Annals of Oncology
·
1
A rise in double-strand breaks sensitizes tumors to oxidative metabolism inhibitors
2026
·
Ferran Medina-Jover
, Agnès Figueras
, et al.
·
Biomedicine & Pharmacotherapy
Convergent stromal and immune remodeling defines spatial tumor dynamics in PARP inhibitor–resistant high-grade serous ovarian cancer
2026
·
Kathleen Jane Imbach
, Sergi Cervilla Garcia
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract P2-03-28: Immune-based gene expression signature determines clinical efficacy of CDK4/6i in HR+HER2- breast cancer
2025
·
Eudald Felip
, Sara Cabrero-De las Heras
, et al.
·
Clinical Cancer Research
75P Defining an immune signature as a CDK4/6i efficacy predictor in HR+HER2- breast cancer
2025
·
E. Garcia-Vidal
, E. Felip Falgas
, et al.
·
ESMO Open
PDF
Abstract B083: Single-cell and spatial transcriptomic characterization of treatment resistance and immune dynamics in high-grade serous ovarian cancer
2024
·
Kathleen J. Imbach
, Vikram Naganathan
, et al.
·
Cancer Research
Supplementary Data from FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
2023
·
Adrià Bernat-Peguera
, Juan Navarro-Ventura
, et al.
PDF
Supplementary Table S1 from FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
2023
·
Adrià Bernat-Peguera
, Juan Navarro-Ventura
, et al.
Show more works
View as search
Works count:
39
Citation count:
571
H-index:
9
I10-index:
9
Year
Topic
Type